Research ExplorerPublicationsIn-vitro activity of avermectins against Mycobacterium ulcer...

In-vitro activity of avermectins against Mycobacterium ulcerans

Standard

In-vitro activity of avermectins against Mycobacterium ulcerans. / Omansen, Till F.; Porter, Jessica L; Johnson, Paul D R; van der Werf, Tjip S; Stienstra, Ymkje; Stinear, Timothy P.

In: PLOS NEGLECT TROP D, Vol. 9, No. 3, 03.2015, p. e0003549.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Omansen, TF, Porter, JL, Johnson, PDR, van der Werf, TS, Stienstra, Y & Stinear, TP 2015, 'In-vitro activity of avermectins against Mycobacterium ulcerans', PLOS NEGLECT TROP D, vol. 9, no. 3, pp. e0003549. https://doi.org/10.1371/journal.pntd.0003549

APA

Omansen, T. F., Porter, J. L., Johnson, P. D. R., van der Werf, T. S., Stienstra, Y., & Stinear, T. P. (2015). In-vitro activity of avermectins against Mycobacterium ulcerans. PLOS NEGLECT TROP D, 9(3), e0003549. https://doi.org/10.1371/journal.pntd.0003549

Vancouver

Omansen TF, Porter JL, Johnson PDR, van der Werf TS, Stienstra Y, Stinear TP. In-vitro activity of avermectins against Mycobacterium ulcerans. PLOS NEGLECT TROP D. 2015 Mar;9(3):e0003549. https://doi.org/10.1371/journal.pntd.0003549

Bibtex

@article{799ad3b7f87940e99ba2302f3c7ecb60,
title = "In-vitro activity of avermectins against Mycobacterium ulcerans",
abstract = "Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there are problems that include reliance on daily streptomycin injections and side effects such as ototoxicity. Trials of all-oral treatments for BU show promise but additional drug combinations that make BU treatment safer and shorter would be welcome. Following on from reports that avermectins have activity against Mycobacterium tuberculosis, we tested the in-vitro efficacy of ivermectin and moxidectin on M. ulcerans. We observed minimum inhibitory concentrations of 4-8 μg/ml and time-kill assays using wild type and bioluminescent M. ulcerans showed a significant dose-dependent reduction in M. ulcerans viability over 8-weeks. A synergistic killing-effect with rifampicin was also observed. Avermectins are well tolerated, widely available and inexpensive. Based on our in vitro findings we suggest that avermectins should be further evaluated for the treatment of BU. ",
keywords = "Administration, Oral, Buruli Ulcer/drug therapy, Ivermectin/analogs & derivatives, Microbial Sensitivity Tests, Mycobacterium ulcerans/drug effects, Rifampin/administration & dosage, Streptomycin/administration & dosage",
author = "Omansen, {Till F.} and Porter, {Jessica L} and Johnson, {Paul D R} and {van der Werf}, {Tjip S} and Ymkje Stienstra and Stinear, {Timothy P}",
year = "2015",
month = mar,
doi = "10.1371/journal.pntd.0003549",
language = "English",
volume = "9",
pages = "e0003549",
journal = "PLOS NEGLECT TROP D",
issn = "1935-2735",
publisher = "Public Library of Science",
number = "3",

}

RIS

TY - JOUR

T1 - In-vitro activity of avermectins against Mycobacterium ulcerans

AU - Omansen, Till F.

AU - Porter, Jessica L

AU - Johnson, Paul D R

AU - van der Werf, Tjip S

AU - Stienstra, Ymkje

AU - Stinear, Timothy P

PY - 2015/3

Y1 - 2015/3

N2 - Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there are problems that include reliance on daily streptomycin injections and side effects such as ototoxicity. Trials of all-oral treatments for BU show promise but additional drug combinations that make BU treatment safer and shorter would be welcome. Following on from reports that avermectins have activity against Mycobacterium tuberculosis, we tested the in-vitro efficacy of ivermectin and moxidectin on M. ulcerans. We observed minimum inhibitory concentrations of 4-8 μg/ml and time-kill assays using wild type and bioluminescent M. ulcerans showed a significant dose-dependent reduction in M. ulcerans viability over 8-weeks. A synergistic killing-effect with rifampicin was also observed. Avermectins are well tolerated, widely available and inexpensive. Based on our in vitro findings we suggest that avermectins should be further evaluated for the treatment of BU.

AB - Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there are problems that include reliance on daily streptomycin injections and side effects such as ototoxicity. Trials of all-oral treatments for BU show promise but additional drug combinations that make BU treatment safer and shorter would be welcome. Following on from reports that avermectins have activity against Mycobacterium tuberculosis, we tested the in-vitro efficacy of ivermectin and moxidectin on M. ulcerans. We observed minimum inhibitory concentrations of 4-8 μg/ml and time-kill assays using wild type and bioluminescent M. ulcerans showed a significant dose-dependent reduction in M. ulcerans viability over 8-weeks. A synergistic killing-effect with rifampicin was also observed. Avermectins are well tolerated, widely available and inexpensive. Based on our in vitro findings we suggest that avermectins should be further evaluated for the treatment of BU.

KW - Administration, Oral

KW - Buruli Ulcer/drug therapy

KW - Ivermectin/analogs & derivatives

KW - Microbial Sensitivity Tests

KW - Mycobacterium ulcerans/drug effects

KW - Rifampin/administration & dosage

KW - Streptomycin/administration & dosage

U2 - 10.1371/journal.pntd.0003549

DO - 10.1371/journal.pntd.0003549

M3 - SCORING: Journal article

C2 - 25742173

VL - 9

SP - e0003549

JO - PLOS NEGLECT TROP D

JF - PLOS NEGLECT TROP D

SN - 1935-2735

IS - 3

ER -